Literature DB >> 3263594

The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.

C Pifl1, G Schingnitz, O Hornykiewicz.   

Abstract

Using high-pressure liquid chromatography with electrochemical detection, we measured dopamine (DA) and homovanillic acid (HVA) in caudate nucleus, putamen and substantia nigra in 4 untreated rhesus monkeys and 4 monkeys with permanent parkinsonism produced by repeated injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; total dose: 2.1-6.45 mg/kg, i.m.). MPTP consistently produced a severe striatal and nigral loss of DA and HVA and an increase in the ratio 'HVA/DA'. In this respect, MPTP mimicked the changes found in human Parkinson's disease (PD). However, MPTP lowered the DA in caudate (-99.6%) to the same degree as in putamen (-99.5%). This is in contrast to idiopathic PD where the caudate is significantly less affected by DA loss (-84%) than the putamen (-98%). Thus, in our rhesus monkeys MPTP failed to reproduce the interregional caudate-putamen gradient characteristic of idiopathic PD. The DA pattern produced by MPTP was similar to the DA loss in caudate (-98%) and putamen (-99%) observed in patients with postencephalitic parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263594     DOI: 10.1016/0304-3940(88)90066-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity.

Authors:  K K Gnanalingham; N A Milkowski; L A Smith; A J Hunter; P Jenner; C D Marsden
Journal:  J Neural Transm Gen Sect       Date:  1995

2.  Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  R Moratalla; B Quinn; L E DeLanney; I Irwin; J W Langston; A M Graybiel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

Review 3.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism.

Authors:  B J Snow; F J Vingerhoets; J W Langston; J W Tetrud; V Sossi; D B Calne
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

Review 5.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

6.  Development of a stable, early stage unilateral model of Parkinson's disease in middle-aged rhesus monkeys.

Authors:  Feng Ding; Liming Luan; Yi Ai; Ashley Walton; Greg A Gerhardt; Don M Gash; Richard Grondin; Zhiming Zhang
Journal:  Exp Neurol       Date:  2008-05-03       Impact factor: 5.330

7.  Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-05       Impact factor: 10.154

Review 8.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.